Perbedaan Indah Kiat Pulp & Paper Tbk. dan Organon Pharma Indonesia Tbk.: Indah Kiat Pulp & Paper Tbk. diperdagangkan di Rp8.850 (kapitalisasi pasar 49,79 T, volume 24 jam 4,85 jt), sedangkan Organon Pharma Indonesia Tbk. diperdagangkan di Rp29.000 (kapitalisasi pasar 104,4 M). Perbedaan utamanya: Indah Kiat Pulp & Paper Tbk. jauh lebih besar — sekitar 476,9× kapitalisasi pasar Organon Pharma Indonesia Tbk.. Mana yang lebih baik tergantung tujuan investasimu.
| INKP | SCPI | |
|---|---|---|
Kapitalisasi Pasar | 49,79 T | 104,4 M |
Volume | 4,85 jt | — |
Lot | 48,54 rb | — |
Perputaran | 43,18 M | — |
Harga Rata-rata | 8.895,47 | — |
Nilai Transaksi | 43,18 M | — |
Harga Ekuilibrium Indikatif | 8.850 | — |
Volume Ekuilibrium Indikatif | 3,11 rb | — |
Imbal hasil berjalan pada periode standar
Berita terbaru kedua aset
PT Indah Kiat Pulp & Paper Tbk (the Company) was established in Jakarta on December 7, 1976. Indah Kiat is one of Asia Pulp & Paper Co. Ltd’s (APP) indirect subsidiaries ano of the largest pulp & paper producer in Asia. The Company had started commercial production as early as 1978 in the Tangerang Mill. At the end of 1999, IKPP had an installed production capacity of more than 3 million tones. Indah Kiat received ISO 9002 QMS (Quality Management System) for compliance with quality system standards in the Perawang, Tangerang and Serang mills. The Company also received ISO 14001 EMS (Environmental Management System) for compliance with the environmental management in the Perawang and Tangerang mills.
Selengkapnya di halaman INKP →PT Merck Sharp Dohme Pharma Tbk was established within the frame work of the Foreign Capital Investment Law No. 1 year 1967 as amended by Law No. 11 year 1970 based on Notarial Deed No. 17 dated 7 March 1972 of Djojo Muljadi, S.H. The company originally incorporated as PT. Essex Indonesia, as a joint venture between Schering Corporation, a worldwide, research-based pharmaceutical enterprise headquartered in the United States, and an Indonesian businessman.
Selengkapnya di halaman SCPI →